Learn the hidden signs of sleep apnea, its impact on health, and how effective treatment can restore your energy and improve ...

Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced that it has been honored with the Research and ...

ORLANDO -- Tirzepatide (Zepbound) improved symptoms of moderate-to-severe obstructive sleep apnea (OSA) in people with obesity, regardless of positive airway pressure (PAP) use, the phase III SURMOUNT ...

A nightly oral pill for obstructive sleep apnea is close to regulatory approval in the US. This medicine-based option could ...

Often brushed off as loud snoring, obstructive sleep apnea is a serious disorder that repeatedly cuts oxygen during sleep, strains the heart and brain, and raises the risk of hypertension, stroke and ...

Incannex Healthcare Limited Sponsored ADR ( (IXHL) ) has provided an announcement.

(Reuters) -The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to directly treat ...

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity. Zepbound is a dual ...

Please provide your email address to receive an email when new articles are posted on . Individuals with moderate to severe obstructive sleep apnea had increased odds of having neovascular AMD.

Medical News Today looks at three key studies and their key findings that highlight and further confirm the connection ...

Sleep apnea affects as many as 80 million in the U.S. Now Apnimed, the $400 million company behind the first ever pill to ...

The Food and Drug Administration has approved Zepbound, a GLP-1 weight-loss drug from Eli Lilly & Co., for the treatment of moderate to severe sleep apnea certain patients with obesity. Photo courtesy ...